139 related articles for article (PubMed ID: 26288837)
1. Development of Polypeptide-based Nanoparticles for Non-viral Delivery of CD22 RNA Trans-splicing Molecule as a New Precision Medicine Candidate Against B-lineage ALL.
Uckun FM; Mitchell LG; Qazi S; Liu Y; Zheng N; Myers DE; Song Z; Ma H; Cheng J
EBioMedicine; 2015 Jul; 2(7):649-59. PubMed ID: 26288837
[TBL] [Abstract][Full Text] [Related]
2. CD22ΔE12 as a molecular target for corrective repair using RNA trans-splicing: anti-leukemic activity of a rationally designed RNA trans-splicing molecule.
Uckun FM; Qazi S; Ma H; Reaman GH; Mitchell LG
Integr Biol (Camb); 2015 Feb; 7(2):237-49. PubMed ID: 25567759
[TBL] [Abstract][Full Text] [Related]
3. CD22ΔE12 as a molecular target for RNAi therapy.
Uckun FM; Ma H; Cheng J; Myers DE; Qazi S
Br J Haematol; 2015 May; 169(3):401-14. PubMed ID: 25659406
[TBL] [Abstract][Full Text] [Related]
4. Identification and targeting of CD22ΔE12 as a molecular RNAi target to overcome drug resistance in high-risk B-lineage leukemias and lymphomas.
Uckun FM; Qazi S
Cancer Drug Resist; 2018; 1():30-47. PubMed ID: 31788667
[TBL] [Abstract][Full Text] [Related]
5. CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemia.
Uckun FM; Goodman P; Ma H; Dibirdik I; Qazi S
Proc Natl Acad Sci U S A; 2010 Sep; 107(39):16852-7. PubMed ID: 20841423
[TBL] [Abstract][Full Text] [Related]
6. Liposomal Nanoparticles of a Spleen Tyrosine Kinase P-Site Inhibitor Amplify the Potency of Low Dose Total Body Irradiation Against Aggressive B-Precursor Leukemia and Yield Superior Survival Outcomes in Mice.
Uckun FM; Myers DE; Cheng J; Qazi S
EBioMedicine; 2015 Jun; 2(6):554-62. PubMed ID: 26285772
[TBL] [Abstract][Full Text] [Related]
7. A rationally designed nanoparticle for RNA interference therapy in B-lineage lymphoid malignancies.
Uckun FM; Qazi S; Ma H; Yin L; Cheng J
EBioMedicine; 2014 Dec; 1(2-3):141-155. PubMed ID: 25599086
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.
Wayne AS; Kreitman RJ; Findley HW; Lew G; Delbrook C; Steinberg SM; Stetler-Stevenson M; Fitzgerald DJ; Pastan I
Clin Cancer Res; 2010 Mar; 16(6):1894-903. PubMed ID: 20215554
[TBL] [Abstract][Full Text] [Related]
9. CD22 Exon 12 deletion is a characteristic genetic defect of therapy-refractory clones in paediatric acute lymphoblastic leukaemia.
Ma H; Qazi S; Ozer Z; Gaynon P; Reaman GH; Uckun FM
Br J Haematol; 2012 Jan; 156(1):89-98. PubMed ID: 22017452
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy with MXD3 siRNA, anti-CD22 antibody and nanoparticles for precursor B-cell acute lymphoblastic leukaemia.
Satake N; Duong C; Chen C; Barisone GA; Diaz E; Tuscano J; Rocke DM; Nolta J; Nitin N
Br J Haematol; 2014 Nov; 167(4):487-99. PubMed ID: 25196579
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.
Haso W; Lee DW; Shah NN; Stetler-Stevenson M; Yuan CM; Pastan IH; Dimitrov DS; Morgan RA; FitzGerald DJ; Barrett DM; Wayne AS; Mackall CL; Orentas RJ
Blood; 2013 Feb; 121(7):1165-74. PubMed ID: 23243285
[TBL] [Abstract][Full Text] [Related]
12. Attenuated measles virus controls pediatric acute B-lineage lymphoblastic leukemia in NOD/SCID mice.
Lühl NC; Zirngibl F; Dorneburg C; Wei J; Dahlhaus M; Barth TF; Meyer LH; Queudeville M; Eckhoff S; Debatin KM; Beltinger C
Haematologica; 2014 Jun; 99(6):1050-61. PubMed ID: 24700491
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia.
Kato J; Satake N; O'Donnell RT; Abuhay M; Lewis C; Tuscano JM
Leuk Res; 2013 Jan; 37(1):83-8. PubMed ID: 23040543
[TBL] [Abstract][Full Text] [Related]
14. Targeting CD22 in B-cell malignancies: current status and clinical outlook.
Sullivan-Chang L; O'Donnell RT; Tuscano JM
BioDrugs; 2013 Aug; 27(4):293-304. PubMed ID: 23696252
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia.
Kinjyo I; Matlawska-Wasowska K; Chen X; Monks NR; Burke P; Winter SS; Wilson BS
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28449314
[TBL] [Abstract][Full Text] [Related]
16. BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells.
Klein F; Feldhahn N; Herzog S; Sprangers M; Mooster JL; Jumaa H; Müschen M
Oncogene; 2006 Feb; 25(7):1118-24. PubMed ID: 16205638
[TBL] [Abstract][Full Text] [Related]
17. Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study.
Chevallier P; Huguet F; Raffoux E; Etienne A; Leguay T; Isnard F; Robillard N; Guillaume T; Delaunay J; Charbonnier A; Pigneux A; Peterlin P; Bené MC; Wegener WA; Goldenberg DM; Dombret H
Haematologica; 2015 Apr; 100(4):e128-31. PubMed ID: 25552705
[No Abstract] [Full Text] [Related]
18. Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia.
Goodman PA; Wood CM; Vassilev A; Mao C; Uckun FM
Oncogene; 2001 Jul; 20(30):3969-78. PubMed ID: 11494125
[TBL] [Abstract][Full Text] [Related]
19. SYK as a New Therapeutic Target in B-Cell Precursor Acute Lymphoblastic Leukemia.
Uckun FM; Qazi S
J Cancer Ther; 2014 Jan; 5(1):124-131. PubMed ID: 24851191
[TBL] [Abstract][Full Text] [Related]
20. Screening of Variations in CD22 Gene in Children with B-Precursor Acute Lymphoblastic Leukemia.
Aslar Oner D; Akin DF; Sipahi K; Mumcuoglu M; Ezer U; Kürekci AE; Akar N
Genet Test Mol Biomarkers; 2016 Sep; 20(9):552-5. PubMed ID: 27486888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
